Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

I-Mab, MorphoSys Announce First Patient Dosed in Study of TJ210/MOR210 for Advanced Cancer

americanpharmaceuticalreviewFebruary 02, 2021

Tag: I-Mab , MorphoSys , TJ210 , MOR210 , Solid Tumors

PharmaSources Customer Service